However, in a cohort of metastatic NSCLC patients with wild type epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) gene and tumor tissue expressing programmed death ligand-1(TPD-L1), treatment mainly comprises of FDA approved immune checkpoint inhibitors (ICIs), anti-programmed death protein 1/programmed death ligand 1 (PD-1/PD-L1) (4). The gene discussed is ALK; the disease is neoplasm.